Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Summit Therapeutics
Pharma
AZ-Summit, Novo-Hengrui, Merck—Fierce Pharma Asia
AstraZeneca invests in Summit, Novo bought a GLP-1/GIP drug from Hengrui, and Merck got a preclinical RAS(ON) inhibitor from China's SciBrunch.
Angus Liu
Oct 2, 2026 9:35am
Fierce Biotech
AstraZeneca scales Summit’s PD-1xVEGF combos with $2B investment
Sep 29, 2026 3:07am
Ivonescimab tops Keytruda with strong OS in PD-L1-high NSCLC
Sep 13, 2026 8:00am
Akeso, Summit’s ivonescimab hits OS goal in Keytruda head-to-head
Sep 3, 2026 10:29am
Akeso CEO touts biliary tract win, counters ivonescimab debate
Aug 26, 2026 11:11am
Generic tariffs, Samsung Bio, HK IPO—Fierce Pharma Asia
Jul 24, 2026 9:00am
